Indication
Details coming soon
Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Cervical Cancer Prevention Age: 9 to and including 14 years |
Dose: Intramuscular Injection – 0.5 ml Frequency: 2 doses given between 5 and 13 months after the first dose Note: If the second vaccine dose is administered before the 5th month after the first dose, a third dose should always be administered. The necessity for a booster dose has not been established. |
|
Indication: Cervical Cancer Prevention Age: 9 to and including 14 years |
Dose: Intramuscular Injection – 0.5 ml Frequency: 3 doses at 0, 1, 6 months Note: The necessity for a booster dose has not been established. |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Cervical Cancer Prevention Age: Girls below 9 years |
Dose: Intramuscular Injection – Not recommended Note: Not recommended for use in girls below 9 years of age |
|
Indication: Cervical Cancer Prevention Age: Children 9 to 14 years |
Dose: Intramuscular Injection – 0.5 ml Frequency: 2 doses Note: The second dose given between 5 and 13 months after the first dose. If the second vaccine dose is administered before the 5th month after the first dose, a third dose should always be administered. Indicated for prevention of cervical precancers and cervical cancer associated with oncogenic HPV types 16 and 18. |
Administration
- Give in deltoid region
- Do not give intravenously
Side Effect
- Human papillomavirus bivalent (Types 16 and 18) vaccine is generally well tolerated
- Most of the above adverse reactions are mild to moderate
- pain
- redness
- and swelling at the injection site
- fatigue
- headache
- myalgia
- gastrointestinal symptoms
- and arthralgia
- Very common Fever (More than 37.1 °C)
- Common Headache
- fatigue
- cough
- muscle pain
- nausea
- diarrhea
- dizziness and vomiting Occasional Hypersensitivity
- allergic dermatitis
- rash
- dizziness and pruritus
- Very common Pain at the injection site
- Common Pruritus
- induration
- swelling and erythema at injection site Occasional Rash and discomfort at injection site
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
Immunosuppressive therapies (e.g. irradiation, cytotoxic drugs, corticorsteroids)
|
May reduce a patient's immune response to the vaccine
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
Acute febrile illness
|
Postpone vaccination
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Store refrigerated at 2 to 8°C. Do not freeze. Protect from light. Human Papillomavirus Bivalent should be administered as soon as possible after being removed from refrigeration.
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.